Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072882 | 0.88 | TSHR (0.59) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL13933523 | 0.81 | TSHR (0.58) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL4073792 | 0.81 | TSHR (0.58) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL4072199 | 0.78 | MCL1 (0.62) | TSHRL3MBTL1LMNAPOLBHTT | |
| SCHEMBL13933506 | 0.77 | TSHR (0.57) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL4073263 | 0.77 | TSHR (0.57) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL14228818 | 0.72 | ALDH1A1 (0.60) | TSHRL3MBTL1KMT2AMEN1CYP2C19 | |
| SCHEMBL8533502 | 0.71 | TSHR (0.69) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL12292116 | 0.69 | TSHR (0.65) | TSHRRECQLL3MBTL1LMNAKMT2A | |
| SCHEMBL4073956 | 0.68 | TP53 (0.41) | TSHRL3MBTL1LMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547933-A | Radiofluorination | BAYER SCHERING PHARMA AG (DE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035215-A1 | RADIOFLUORINATION | AFF2, AFF1, NUTF2 | TSHR 203/4885RECQL 730/4885L3MBTL1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.